Logo

Castle Biosciences: Kristen Oelschlager

Apr 12, 2021
Castle Biosciences has appointed Kristen Oelschlager as chief operating officer. Oelschlager had been serving as the company's chief operations officer since August 2020. Prior to that, she served as senior vice president of clinical operations from January 2018 to August 2020, VP of clinical operations from 2013 to 2018, and executive director of operations from October 2008 to 2013. Oelschlager also served as director of clinical research for Arizona Pulmonary Specialists from May 1996 to September 2008.
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.